News | May 07, 2008

Contrast ECG Registry Explores Safety Concerns

May 7, 2008 – Lantheus Medical Imaging initiated CaRES (Contrast Echocardiography REgistry for Safety Surveillance), a multicenter Phase IV observational study that will further evaluate the safety profile of DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension in patients with suboptimal echocardiograms, to explore the safety profile of DEFINITY for which the FDA posted an alert on Oct. 10, 2007.

In post-marketing use, four patients experienced fatal cardiac arrests either during or within 30 minutes of DEFINITY administration; one patient received DEFINITY and underwent a cardiac stress test, two patients had severe congestive heart failure and the fourth was undergoing mechanical ventilation for respiratory failure.

The open-label, nonrandomized registry will be conducted in at least 10 clinical sites in the U.S. and include at least 1,600 patients. The study will gather data on patient characteristics and demographics, indication for the contrast usage, safety monitoring of patients during and after DEFINITY administration and nature and frequency of any adverse events that may occur.

“The CaRES registry was established following discussions with the FDA to further explore the safety profile of DEFINITY as it is used in clinical practice. We believe this is the first large multi-center safety registry of its kind to be performed in the U.S.," said Mark Hibberd, M.D., Senior Medical Director, Lantheus Medical Imaging. "We expect the study to provide the physician community with important information about the safety profile of DEFINITY in patients with suboptimal non-contrast echo studies."

Activated DEFINITY Vial for (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The agent currently carries the “black box” warning from the FDA. The safety and efficacy of DEFINITY with exercise stress or pharmacologic stress testing have not been established.

For more information: http://www.fda.gov/CDER/drug/InfoSheets/HCP/microbubbleHCP.htm and http://www.nmh.org/nmh/heart/coronarydisease/main.htm

Related Content

ITN Wins Jesse H. Neal Award for Best Technical Content
News | Radiology Business | April 24, 2019
April 24, 2019 — Imaging Technology News (ITN) was recently named the 2019 Jesse H.
Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...